100,000 Shares in Keros Therapeutics, Inc. $KROS Bought by Stonepine Capital Management LLC

Key Points

• Stonepine Capital Management LLC has acquired 100,000 shares of Keros Therapeutics, valued at approximately $1,019,000, making it the firm's 21st largest holding.
• Analysts have reduced price targets for Keros Therapeutics, with HC Wainwright lowering its target from $25 to $20, while Bank of America cut its rating from "buy" to "neutral" with a new target of $18.
• Keros Therapeutics reported a quarterly EPS of ($0.76), which exceeded analysts' estimates, and a revenue increase of over 49,000% compared to the same quarter last year, despite only generating $0.02 million in revenue.

Stonepine Capital Management LLC acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The fund acquired 100,000 shares of the company's stock, valued at approximately $1,019,000. Keros Therapeutics makes up about 1.0% of Stonepine Capital Management LLC's holdings, making the stock its 21st largest position. Stonepine Capital Management LLC owned 0.25% of Keros Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. 22NW LP purchased a new stake in shares of Keros Therapeutics during the first quarter worth about $1,824,000. Jump Financial LLC purchased a new stake in shares of Keros Therapeutics during the first quarter worth about $1,058,000. AlphaQuest LLC grew its position in shares of Keros Therapeutics by 268.0% during the first quarter. AlphaQuest LLC now owns 13,234 shares of the company's stock worth $135,000 after purchasing an additional 9,638 shares in the last quarter. Algert Global LLC grew its position in shares of Keros Therapeutics by 116.4% during the first quarter. Algert Global LLC now owns 27,480 shares of the company's stock worth $280,000 after purchasing an additional 14,783 shares in the last quarter. Finally, Tejara Capital Ltd purchased a new stake in shares of Keros Therapeutics during the first quarter worth about $410,000. Hedge funds and other institutional investors own 71.56% of the company's stock.

Keros Therapeutics Stock Performance

NASDAQ KROS traded down $0.26 on Friday, reaching $15.00. 79,241 shares of the stock traded hands, compared to its average volume of 959,020. The company has a fifty day moving average price of $14.16 and a 200-day moving average price of $13.10. The company has a market cap of $609.02 million, a price-to-earnings ratio of 48.21, a PEG ratio of 2.00 and a beta of 1.33. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $3.83 million. During the same period last year, the business posted ($1.25) EPS. The business's revenue was up 49002.7% compared to the same quarter last year. As a group, research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on KROS. Scotiabank cut their price target on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a report on Monday, May 12th. HC Wainwright cut their price target on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a report on Friday, August 8th. Bank of America cut Keros Therapeutics from a "buy" rating to a "neutral" rating and cut their price target for the company from $32.00 to $18.00 in a report on Tuesday, June 10th. Finally, Wedbush restated a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a report on Friday, May 30th. Seven research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $30.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.